Truist raised the firm’s price target on Insmed (INSM) to $108 from $105 and keeps a Buy rating on the shares after its Q4 results. With the pre-announced Arikayce FY24 sales and FY25 guidance reiterated on Q4 EPS call, there were no surprises, while the company also reiterated its focus on setting up for a successful commercial launch ahead of a potential brenso PDUFA on August 12, the analyst tells investors in a research note. Truist is “remaining buyers” into Insmed’s inflection points in 2025, the firm adds.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed price target lowered to $96 from $97 at Stifel
- Insmed’s Strategic Growth Potential and Market Opportunities Justify Buy Rating
- Insmed’s Strong 2024 Growth and Promising Pipeline
- Ritu Baral’s Buy Rating for Insmed Supported by Strong Financials and Promising Pipeline
- Insmed Board Member Alfred Altomari to Step Down